Skip to main content
News Icon

New Speaker and Executive Board Member

Prof. Joachim L. Schultze from the LIMES Institute Bonn resigned in his position as speaker and member of the executive board of the Cluster of Excellence.

We wish him all the best for his future tasks in the field of immunology and we are more then happy that he supports the Cluster of Excellence ImmunoSensation as a member of the steering committe and valuable group leader.

As a succesor for the speaker position Prof. Waldemar Kolanus and as succesor for the executive board member position Prof. Elvira Mass, both from the LIMES Institute in Bonn, will replace Prof. Joachim L. Schultze.

Welcome Prof. Kolanus and Prof. Mass in your new roles in the Cluster of Excellence ImmunoSensation2.

Related news

Children in the lab at "Girls' and Boys' Day 2026"

Outreach

Girls' & Boys' Day at ImmunoSensation³

—The annual "Girls' & Boys' Day" (former "Girls' day") sets out to introduce children and young addults to careers their respective gender is still underrepresented in. To celebrate this special day and offer insights into the work of a biomedical researcher, we welcomed students from all over Germany to our laboratories. Besides hands-on science, career options and perspectives in research were discussed.
View entry
PM Immunity Nebeling

Publication

Study reveals dynamic interactions between brain tumors and immune cells

—Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry
Nora Möhn

Publication

New Findings on Immunotherapy for a Rare Brain Infection

—Progressive multifocal leukoencephalopathy (PML) is a rare but very serious brain disease. It is caused by the reactivation of the widespread JC virus when the immune system is severely weakened. There is currently no targeted antiviral therapy available, which is why new treatment approaches are urgently needed. In recent years, so-called immune checkpoint inhibitors have been increasingly used; these “unlock” the immune system and reactivate the body’s own immune cells. The results were recently published in the journal JAMA Neurology.
View entry

Back to the news overview